High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group
- 1 September 1995
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 31 (10) , 1622-1626
- https://doi.org/10.1016/0959-8049(95)00193-m
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Chemotherapy for hormonally refractory advanced prostate carcinoma. A Comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracilCancer, 1992
- The role of chemotherapy in refractory prostate cancerCurrent Opinion in Urology, 1991
- Prostatic Specific AntigenBritish Journal of Urology, 1991
- Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease.Journal of Clinical Oncology, 1990
- Low-dose fortnightly methotrexate in advanced prostate cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- Is There a Place for Chemotherapy in Advanced Prostatic Cancer?American Journal of Clinical Oncology, 1988
- Mitomycin-C in the treatment of metastatic prostate cancer: report on an EORTC phase II studyWorld Journal of Urology, 1986
- Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?Journal of Clinical Oncology, 1985
- An EORTC phase II study of vindesine in advanced prostate cancerEuropean Journal of Cancer and Clinical Oncology, 1983
- Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostateCancer, 1979